Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
Cancer is any malignant growth or tumor caused by abnormal and uncontrolled cell division. It may spread to other parts of the body through the lymphatic system or the blood stream. Cancer includes the two broad categories of carcinoma and sarcoma, but in normal usage it is often used synonymously with carcinoma.
logo - spiritindia - Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT

Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine

Cancer :: Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine

Cancer :: Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine

Researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announces that a poster by Dr. Maureen E. Lane et al. of Cornell University, New York, entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" is scheduled to be presented today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, CA. The meeting runs from April 14-18, 2007.

The researchers found that treatment of human colon cancer cell lines with the combination of REOLYSIN? and gemcitabine resulted in both in vitro and in vivo synergy. There was no toxicity associated with the combined treatment. Tumours treated with the combination were significantly smaller (by area and weight) than tumours in control groups or tumours treated with either agent alone. The researchers concluded that the synergistic combination of REOLYSIN? and gemcitabine is a promising therapeutic regimen for study in clinical trials.

"It is rare to see the virtual elimination of tumours as well as the long-lasting therapeutic effect that we have observed from this study," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are very encouraged by these results and look forward to testing this particular treatment combination in our upcoming human systemic administration trial in the U.K."

(Cancer :: Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine published at SpiritIndia on Wednesday, April 18, 2007)

Search more information on Cancer

Recently posted related articles on Cancer :

  1. Liver Cancer :: Nexavar approved for patients with inoperable liver cancer
  2. Cancer :: Scientific evidence of the significant anti-cancer effect of milk thistle
  3. Breast Cancer :: Normal tissue not spared in new forms of breast cancer radiotherapy
  4. Breast Cancer :: Drug Could Effectively Treat, Prevent the Spread of Breast Cancer
  5. Oral Cancer :: USC School of Dentistry researchers discover link between oral cancer and ethnicity
  6. Ovarian Cancer :: New Therapy for Patients with Platinum-Resistant Ovarian Cancer
  7. Prostate Cancer :: Obesity and overweight linked to higher prostate cancer mortality
  8. Cancer :: Caregivers benefit from cancer support programs, U-M study finds
  9. Lung Cancer :: Tumor genome analysis unveils new insights into lung cancer
  10. Cancer :: American Association for Cancer Research announces AACR Asia

»»   Lung Cancer :: Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
««   Healthcare :: Should researchers wash their hands of hand washing?

Tools
Daily calorie need
Homeo tips
Homeo softwares
Associations
NHMC Alumni
IFH
PHS
Vital Informer
Articles & news
Education
Homeo articles
Homeopathy cases
Homeopathic Remedies
You
Authors
Submit article
Your account
Testimonials
About
About us
Advertisers
Advertising
Linking us
Disclaimer
Privacy policy

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com